Novo Nordisk A (NVO) stock analysis

Healthcare · Drug Manufacturers - General

From the 20-F filed 2026-02-04

Business type: Franchise

How it makes money

It generates profit from GLP-1 receptor agonists Ozempic and Wegovy, which respectively contributed DKK 127 billion and DKK 79 billion in 2025 revenue.

Profits depend on the sales volume of injectable semaglutide products for diabetes and obesity. The company also generates revenue from its newly launched Wegovy Pill and a portfolio of insulins.

While Novo Nordisk is a global leader, it faces volume market share losses to a primary competitor. Revenue is primarily paid by insurers and government programs like Medicare Part D, where negotiated price caps will take effect in 2027.

What protects it: the moat

It defends its semaglutide franchise with a US compound patent lasting until 2032 and confidential settlements with manufacturers filing for generic drug approvals.

Legal protection is maintained through litigation against Abbreviated New Drug Applications and Patent Trial and Appeal Board challenges. In China, the Supreme People's Court recognized the validity of its semaglutide compound patent in 2025.

Competitive advantages are sustained by high-complexity aseptic production facilities and a global distribution network that smaller biotech rivals lack the capital to replicate.

What growth costs

It is investing DKK 49.6 billion in Kalundborg and DKK 27.0 billion in North Carolina to expand aseptic manufacturing and API production capacity.

Growth requires allocating 15-17% of sales to R&D, primarily for clinical trials like the Phase 3 CagriSema program. Capital expenditures are focused on internalizing production to resolve periodic supply constraints.

Recent inorganic growth includes the 4.7 billion USD acquisition of Akero Therapeutics to secure treatments for metabolic dysfunction-associated steatohepatitis.

What could damage it

Medicare Part D price negotiations starting in 2027 and compounding pharmacies selling unapproved semaglutide copies threaten its long-term profit margins and market control.

Earnings are threatened by compounding pharmacies that continue to distribute unapproved copies of its anti-obesity drugs after official drug shortages are resolved.

Furthermore, the loss of prescription leadership to a primary competitor's GLP-1 product in early 2025 signals a shift in market volume dominance and pricing power.

About Novo Nordisk A

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Plus, smart insulin pens; Dose Check, an insulin dose guidance application; growth hormone pens and injection needles; and Wegovy pill an oral glucagon-like peptide-1 (GLP-1) receptor agonist therapy for weight management. The company has a collaboration with Anthropic accelerate the development of new medicines and advance AI-driven software development. It operates in Europe, Canada, the United States, Japan, Korea, Oceania, Southeast Asia, Mainland China, Hong Kong and Taiwan, Latin America, the Middle East, and Africa. It has a strategic collaboration with Orbis Medicines to discover and develop oral macrocycle therapeutics for cardiometabolic diseases. The company was formerly known as Novo Industri A/S and changed its name to Novo Nordisk A/S in April 1989. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Other companies in Drug Manufacturers - General